RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Checkmate Pharmaceuticals Stock

Checkmate Pharmaceuticals ROE 2024

Checkmate Pharmaceuticals ROE

-0.88

Ticker

CMPI

ISIN

US1628181083

WKN

A2QAMD

In 2024, Checkmate Pharmaceuticals's return on equity (ROE) was -0.88, a 0% increase from the 0 ROE in the previous year.

Checkmate Pharmaceuticals Aktienanalyse

What does Checkmate Pharmaceuticals do?

Checkmate Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2015 and specializes in the research and development of immuno-oncology therapies. The company has an innovative business model aimed at improving the immune response against cancer. It utilizes the natural ability of the immune system to recognize and eliminate cancer cells. Immuno-oncology is a major trend in cancer therapy today, with the goal of harnessing the body's own immune system to fight cancer cells. Checkmate Pharmaceuticals focuses on the development of unique first-in-class immunotherapeutics. The company collaborates closely with leading academic institutions and international organizations to maximize the potential of its technology and achieve the best results. The business of Checkmate Pharmaceuticals can be divided into three areas, from the Checkmate platform technology, for which multiple patents have been filed, to the two products: CMP-001 (classified as Breakthrough Therapy) and CMP-003. The Checkmate platform technology is based on stimulating immune responses through the ligation of oligonucleotides, which in turn is intended to promote the recognition and elimination of cancer cells. This method aims to safely and effectively harness the benefits of immunotherapy and successfully control the potential hazards of the immune system. CMP-001 is an immunotherapeutic currently in phase 2a clinical development. It is a combination of an adjuvant called STING agonists (also known as Sting-Signalling agonist) and a toll-like receptor-ligand of nucleotide (TLR-9), which help stimulate the body's immune system and trigger an immune response against cancer cells. CMP-001 has been granted 'Breakthrough Therapy' status by the US FDA, meaning that the drug offers a significant advancement in the treatment of patients with serious or life-threatening diseases compared to currently available therapies. CMP-003 is another development by Checkmate Pharmaceuticals, aiming to regulate excessive immune response. Along with STING, antibodies against poxviruses have been shown to activate the immune system and enable effective tumor therapy. One of the main target populations for Checkmate Pharmaceuticals is patients with various types of tumors such as melanoma, small cell lung cancer, and solid tumors that respond to immune system stimulation. Currently, the company is financed by renowned capital investors such as F-Prime Capital, HBM Healthcare Investments, and Sofinnova Investments. The company offers promising perspectives in cancer research and has the potential to deliver further advancements in the field of immuno-oncology with new products. These developments can help make cancer therapy more effective and safer, ultimately moving towards the goal of fighting cancer. Checkmate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Checkmate Pharmaceuticals's Return on Equity (ROE)

Checkmate Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Checkmate Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Checkmate Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Checkmate Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Checkmate Pharmaceuticals stock

What is the ROE (Return on Equity) of Checkmate Pharmaceuticals this year?

The ROE of Checkmate Pharmaceuticals this year is -0.88 undefined.

How has the Return on Equity (ROE) of Checkmate Pharmaceuticals developed compared to the previous year?

The ROE of Checkmate Pharmaceuticals has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Checkmate Pharmaceuticals?

A high ROE indicates that Checkmate Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Checkmate Pharmaceuticals?

A low ROE can indicate that Checkmate Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Checkmate Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Checkmate Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Checkmate Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Checkmate Pharmaceuticals?

Some factors that can influence Checkmate Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Checkmate Pharmaceuticals pay?

Over the past 12 months, Checkmate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Checkmate Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Checkmate Pharmaceuticals?

The current dividend yield of Checkmate Pharmaceuticals is .

When does Checkmate Pharmaceuticals pay dividends?

Checkmate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Checkmate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Checkmate Pharmaceuticals located?

Checkmate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Checkmate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Checkmate Pharmaceuticals from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Checkmate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Checkmate Pharmaceuticals in the year 2023?

In the year 2023, Checkmate Pharmaceuticals distributed 0 USD as dividends.

In which currency does Checkmate Pharmaceuticals pay out the dividend?

The dividends of Checkmate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Checkmate Pharmaceuticals

Our stock analysis for Checkmate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Checkmate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.